2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery …
G Hindricks, T Potpara, N Dagres, E Arbelo… - European heart …, 2021 - academic.oup.com
MicroRNAs (miRNAs) are small regulatory molecules post-transcriptionally suppressing
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …
mRNA activity. Many miRNAs in various organisms have been cloned but many unknown …
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
J Steffel, P Verhamme, TS Potpara… - European heart …, 2018 - academic.oup.com
The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …
Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States
KC Siontis, X Zhang, A Eckard, N Bhave… - Circulation, 2018 - Am Heart Assoc
Background: Patients with end-stage kidney disease (ESKD) on dialysis were excluded from
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …
clinical trials of direct oral anticoagulants for atrial fibrillation (AF). Recent data have raised …
Non–vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction
Background: Dose reduction of non–vitamin K antagonist oral anticoagulants (NOACs) is
indicated in patients with atrial fibrillation (AF) with renal impairment. Failure to reduce the …
indicated in patients with atrial fibrillation (AF) with renal impairment. Failure to reduce the …
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care
Y Vinogradova, C Coupland, T Hill, J Hippisley-Cox - bmj, 2018 - bmj.com
Objective To investigate the associations between direct oral anticoagulants (DOACs) and
risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality …
risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality …
Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants
AJ Camm, F Cools, S Virdone, JP Bassand… - Journal of the American …, 2020 - jacc.org
Background The recommended doses for direct oral anticoagulants (DOACs) to prevent
stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) are described in …
stroke and systemic embolism (SE) in patients with atrial fibrillation (AF) are described in …
Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: A nationwide propensity score–weighted study
Background: Gastrointestinal bleeding (GIB) rates for direct oral anticoagulants (DOACs)
and warfarin have been extensively compared. However, population-based studies …
and warfarin have been extensively compared. However, population-based studies …
Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral …
V Allan, SV Ramagopalan… - Journal of …, 2020 - becarispublishing.com
After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke
prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and …
prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and …
Frequency and outcomes of reduced dose non–vitamin K antagonist anticoagulants: results from ORBITAF II (the outcomes Registry for better informed treatment of …
BA Steinberg, P Shrader, K Pieper… - Journal of the …, 2018 - Am Heart Assoc
Background Non–vitamin K antagonist oral anticoagulants (NOACs) are indicated for stroke
prevention in atrial fibrillation (AF) but require lower doses in certain patients. We sought to …
prevention in atrial fibrillation (AF) but require lower doses in certain patients. We sought to …
Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis
Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …